Kid’s with ADHD and parents who are willing to throw caution out the window are sure to help the penny stock of Neurogenesis Inc. (NEUN) become the next pharmaceutical company to make it big. The company’s headline attraction, NeuBecalm’d is claimed to be a natural alternative to drugged up ADHD kids who are experiencing side effects, such as nervousness, insomnia, loss of appetite, headache, nausea, or stunted growth. Since it’s an obvious choice that every parent whose kid is not just bouncing off the walls uncontrollably, but throwing up everywhere and being the shortest kid on the soccer team, NEUN stock is probably just a few trades away from gaining the attention of some huge drug giant for a hostile takeover bid (or atleast that is what you’re supposed to think).
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
NEUN Stock Quote
Market Cap: 782.38K
Last: 0.01 ▲ +0.0015 (+17.65%)
Volume: 100,100
Dollar Volume: $1,341
Open: 0.015
High: 0.015
Low: 0.01
Trades: 3
Authorized: 1,000,000,000
Issued and Outstanding: 78,238,850
14-Day Rel Strength: 44.37%
1st Resistance Point: 0.0133
1st Support Level: 0.00833
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
With sales of $104,536 for the 3 months ended September 30, 2013, it’s a good thing that Neurogenesis got their OTCMarkets filings done 2 days ago so that NEUN stock could be bagged up just in time for the weekend. With costs of less than 10%, $10,132, to produce those sales, which pharma giant wouldn’t be sending representatives on a plane with briefcases full of money to try and buy the company out?
The company’s headliners, NeuBecalm’d, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm’d Chewables that reduces the effects of stress; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol, are the main selling point for Neurogenesis. The sales channel, as seen on www.fightadd.com, is pretty poorly managed it would seem for a line f products that can produce a 90% gross profit on sales produced.
But, focusing on the sales channel and how Al Bieser, President and CEO of Neurogenesis, runs his program is petty. Heck, once you see and hear the testimonials, you too will probably be running out to see where you can get some NeuBecalm’d:
With all this and a bag of chips, NEUN stock is due to be an explosive percentage gainer with some relatively low dollar volume today. If the chart above doesn’t indicate to you how this “uncompensated pick” is due to play out in the next few hours, perhaps you should stick to trading big board stocks.
About NEUN Stock
Neurogenesis Inc. is a development stage company that ffers an array of natural supplement products which are meant to provide a long lasting solution to chemical imbalances in the brain.
Click here to view the financial filings for NEUN.
Click here to view the website for Neurogenesis.
Last 5 Trading Sessions:
| Date | Open | High | Low | Last | Change | % Change | Volume |
| 11/20/13 | 0.0150 | 0.0150 | 0.0100 | 0.0100 | +0.0015 | +17.65% | 100,100 |
| 11/18/13 | 0.0085 | 0.0085 | 0.0085 | 0.0085 | +0.0007 | +8.97% | 29,600 |
| 11/15/13 | 0.0078 | 0.0078 | 0.0078 | 0.0078 | unch | unch | 100 |
| 11/14/13 | 0.0078 | 0.0078 | 0.0078 | 0.0078 | +0.0001 | +1.30% | 2,500 |
| 11/13/13 | 0.0077 | 0.0077 | 0.0077 | 0.0077 | unch | unch | 9,400 |
Bottom Line:
Depending on how quickly you can buy and sell, NEUN may be worth a $300 look-see if desperate measures have strangled other penny stocks you’re tracking for Thursday. The probability of seeing a huge percentage gain turn into a flat churn of a mid-morning session are about as likely with NEUN as they are with any uncompensated pick that has 78,238,850 share outstanding and just 2 days ago miraculously updated their filings.
Stay Connected With Us:
Our Next Pick Is Coming Soon!
Text Keyword “AIMHIGH” To 99000 To Make Sure You Don’t Miss It!
NOV
